Digest Network Come funziona
Network
/
Società
Ma
Non verificato

MaaT Pharma

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

49 comunicati stampa

Guarda tutti i comunicati
19/10/2026
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Oncologia
Industria
MaaT Pharma Receives FDA Feedback Following Pre-IND Meeting Supporting Continued Development of MaaT034 in Solid Tumors
Fonte
MaaT Pharma
Emittente
Business Wire
1.00
0
29/09/2026
Pubblico Esercizio/Vendita al dettaglio
Mercato azionario
Scienza
Finanza
Medicina - Varie
Associazioni/Professionisti
Biotecnologia
Salute
Farmaceutica
Oncologia
MaaT Pharma Publishes its Half-Year 2026 Results and Provides a Business Update
Fonte
MaaT Pharma
Emittente
Business Wire
1.00
0
21/09/2026
Industria
Eventi
Scienza
Igiene alimentare
Medicina - Varie
Sanità
Farmaceutica
Salute
Oncologia
MaaT Pharma Announces Upcoming Pre-IND Meeting with the FDA and Advances MaaT034 Toward Clinical Development in Solid Tumors
Fonte
MaaT Pharma
Emittente
Business Wire
1.00
0
18/09/2026
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Industria
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination
Fonte
MaaT Pharma
Emittente
Business Wire
1.00
0
15/09/2026
Biotecnologia
Farmaceutica
Salute
Oncologia
Industria
MaaT Pharma Receives Negative CHMP Trend Vote for MaaT013 (Xervyteg®) Following Re-Examination for its Conditional Marketing Authorization Application in Europe
Fonte
MaaT Pharma
Emittente
Business Wire
1.00
0
06/07/2026
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
MaaT Pharma Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract
Fonte
MaaT Pharma
Emittente
Business Wire
1.00
0
26/06/2026
Industria
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
MaaT Pharma Announces Plan to Request Re-Examination Following Negative CHMP Opinion for MaaT013 for the treatment of acute Graft-versus-Host Disease
Fonte
MaaT Pharma
Emittente
Business Wire
1.00
0
26/05/2026
Pubblico Esercizio/Vendita al dettaglio
Eventi
Mercato azionario
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Oncologia
MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026
Fonte
MaaT Pharma
Emittente
Business Wire
1.00
0
20/05/2026
Oncologia
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Industria
MaaT Pharma Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg®) in the treatment of acute Graft-versus-Host Disease
Fonte
MaaT Pharma
Emittente
Business Wire
1.00
0
01/04/2026
Industria
Eventi
Scienza
Oncologia
Sanità
Salute
Medicina - Varie
MaaT Pharma Announces Publication of Retrospective Data in Third-Line Acute GvHD from the CHRONOS Study in Bone Marrow Transplantation Journal
Fonte
MaaT Pharma
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0